Your browser doesn't support javascript.
loading
Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
De Smet, Frederik; Saiz Rubio, Mirian; Hompes, Daphne; Naus, Evelyne; De Baets, Greet; Langenberg, Tobias; Hipp, Mark S; Houben, Bert; Claes, Filip; Charbonneau, Sarah; Delgado Blanco, Javier; Plaisance, Stephane; Ramkissoon, Shakti; Ramkissoon, Lori; Simons, Colinda; van den Brandt, Piet; Weijenberg, Matty; Van England, Manon; Lambrechts, Sandrina; Amant, Frederic; D'Hoore, André; Ligon, Keith L; Sagaert, Xavier; Schymkowitz, Joost; Rousseau, Frederic.
  • De Smet F; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Saiz Rubio M; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Hompes D; Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Naus E; The Broad Institute, Cambridge, MA, USA.
  • De Baets G; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Langenberg T; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Hipp MS; Department of Abdominal Surgery, University Hospitals Gasthuisberg, Leuven, Belgium.
  • Houben B; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Claes F; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Charbonneau S; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Delgado Blanco J; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Plaisance S; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Ramkissoon S; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Ramkissoon L; Department of Cellular Biochemistry, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Simons C; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • van den Brandt P; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Weijenberg M; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Van England M; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Lambrechts S; Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Amant F; The Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • D'Hoore A; VIB Center for Brain and Disease Research, Leuven, Belgium.
  • Ligon KL; Nucleomics Core, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.
  • Sagaert X; Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Schymkowitz J; Department of Pathology, Division of Neuropathology, Brigham and Women's Hospital and Children's Hospital Boston, Boston, MA, USA.
  • Rousseau F; Department of Pathology, Harvard Medical School, Boston, MA, USA.
J Pathol ; 242(1): 24-38, 2017 05.
Article en En | MEDLINE | ID: mdl-28035683
ABSTRACT
Although p53 protein aggregates have been observed in cancer cell lines and tumour tissue, their impact in cancer remains largely unknown. Here, we extensively screened for p53 aggregation phenotypes in tumour biopsies, and identified nuclear inclusion bodies (nIBs) of transcriptionally inactive mutant or wild-type p53 as the most frequent aggregation-like phenotype across six different cancer types. p53-positive nIBs co-stained with nuclear aggregation markers, and shared molecular hallmarks of nIBs commonly found in neurodegenerative disorders. In cell culture, tumour-associated stress was a strong inducer of p53 aggregation and nIB formation. This was most prominent for mutant p53, but could also be observed in wild-type p53 cell lines, for which nIB formation correlated with the loss of p53's transcriptional activity. Importantly, protein aggregation also fuelled the dysregulation of the proteostasis network in the tumour cell by inducing a hyperactivated, oncogenic heat-shock response, to which tumours are commonly addicted, and by overloading the proteasomal degradation system, an observation that was most pronounced for structurally destabilized mutant p53. Patients showing tumours with p53-positive nIBs suffered from a poor clinical outcome, similar to those with loss of p53 expression, and tumour biopsies showed a differential proteostatic expression profile associated with p53-positive nIBs. p53-positive nIBs therefore highlight a malignant state of the tumour that results from the interplay between (1) the functional inactivation of p53 through mutation and/or aggregation, and (2) microenvironmental stress, a combination that catalyses proteostatic dysregulation. This study highlights several unexpected clinical, biological and therapeutically unexplored parallels between cancer and neurodegeneration. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Neoplasias del Colon / Glioblastoma / Cuerpos de Inclusión Intranucleares / Deficiencias en la Proteostasis / Agregación Patológica de Proteínas Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Neoplasias del Colon / Glioblastoma / Cuerpos de Inclusión Intranucleares / Deficiencias en la Proteostasis / Agregación Patológica de Proteínas Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article